A Phase III, multi-center, open-label, randomized, controlled study of the efficacy and safety of oral LDE225 versus temozolomide in patients with Hh-pathway activated relapsed medulloblastoma

Project: Research project

Project Details

StatusFinished
Effective start/end date3/1/131/31/18

Funding

  • Novartis Pharmaceuticals Corporation